BCX — Bioceltix SA Income Statement
0.000.00%
Last trade - 00:00- PLN561.39m
- PLN529.48m
Annual income statement for Bioceltix SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | PAS | PAS | PAS | PAS | PAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.011 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -0.468 | -0.854 | -0.7 | -1.04 | -1.43 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 2.39 | 4.34 | 8.9 | 14 | 15 |
| Operating Profit | -2.38 | -4.34 | -8.9 | -14 | -15 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -2.37 | -4.36 | -8.97 | -13.7 | -14.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.35 | -4.4 | -8.92 | -13.7 | -14.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -2.35 | -4.4 | -8.92 | -13.7 | -14.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.35 | -4.4 | -8.92 | -13.7 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.715 | -1.4 | -2.68 | -3.49 | -3.29 |
| Dividends per Share |